Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05194566 · ClinicalTrials.gov registry record · NA
Neurostimulation for the Treatment of Post-Stroke Aphasia
A NA study of Post-stroke Aphasia, sponsored by Qviti S.A..
- Recruiting
- Registry status
- NA
- Development phase
- 64
- Enrollment target
- 2
- Study locations
NCT05194566: Recruiting NA study of Post-stroke Aphasia, sponsored by Qviti S.A..
NCT05194566 is a NA study of Post-stroke Aphasia that is actively recruiting participants, run by Qviti S.A.. The registered enrollment target is 64 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05194566, a NA study of Post-stroke Aphasia, is actively recruiting participants, sponsored by Qviti S.A..
- RECRUITING
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
- 2
- Study locations
Study Summary
The aim of the trial is to determine whether 75Hz transcranial alternating current stimulation (tACS) synchronized with therapeutic linguistic tasks is an effective form of therapy for post-stroke aphasia.
Primary Outcome
The Baseline Naming Task consists of 344 images representing nouns and the images will be presented on the computer screen. The task is to name the presented noun by producing the name of the item out loud. The answer is scored on a three-point scale (1 - not able to name correctly, 2 - named with phonological or semantic paraphasia, 3 - correct). Items marked with a score of 3 are considered accurate. From the baseline assessment, a random list of 50 incorrectly named words will be trained in t
Conditions Studied
Interventions
- DEVICE tACS
Study Locations (2)
Illinois
- Think & Speak Lab at Shirley Ryan AbilityLab - Chicago
New York
- Abilities Research Center at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-09-06 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT05194566 shows while recruiting
NCT05194566 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Post-stroke Aphasia appearing as the primary indexed condition, and to 1 intervention - of which tACS is the first listed.
NCT05194566 reports a single indexed study location in Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT05194566 about?
NCT05194566 is a clinical study titled "Neurostimulation for the Treatment of Post-Stroke Aphasia". The aim of the trial is to determine whether 75Hz transcranial alternating current stimulation (tACS) synchronized with therapeutic linguistic tasks is an effective form of therapy for post-stroke aphasia.
What is the current status of trial NCT05194566?
This trial is currently recruiting. It is a NA study. The enrollment target is 64 participants. The study started on 2023-09-06. Estimated completion is 2026-12.
What conditions does trial NCT05194566 study?
This clinical trial studies the following conditions: Post-stroke Aphasia.
What interventions are being tested in trial NCT05194566?
The interventions under investigation include: tACS (DEVICE).
Who is sponsoring clinical trial NCT05194566?
This trial is sponsored by Qviti S.A., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05194566 being conducted?
This trial has 2 study locations across Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05194566's enrollment target sits among peer trials
64 1148th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI